NovaBridge Biosciences: accounts_receivable
| Value | {"amount": 20000000, "concept": "us-gaap:AccountsReceivableNetCurrent", "currency": "USD"} |
|---|---|
| Period | (as of 2020-12-31) |
| Status | current |
| Entity | NovaBridge Biosciences |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/77747e4e-92d5-4bb3-9523-14af40559039
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001193125-21-135440Retrieved: 2026-08-19T18:00:43.919806+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001778016/accounts-receivable/2020-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/77747e4e-92d5-4bb3-9523-14af40559039
History
- supersedes {"unit": "CNY", "value": 130498000, "concept": "us-gaap:AccountsReceivableNetCurrent"} (evidence 0001193125-21-135440)